OR WAIT null SECS
At ATTD 2023, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, have an extended conversation with the new chief operating officer at Dexcom, Jake Leach, to discuss the global and US rollouts of the Dexcom G7 and what the future might hold for Dexcom.
On February 17, US availability of the Dexcom G7 became a long-awaited reality for people with diabetes.1
Approved by the US Food and Drug Administration on December 8, 2022, for people with all types of diabetes ages two years and older2, US communities had been made to wait in anticipation as Dexcom had already begun a global rollout months earlier.3 With approval from the US Centers for Medicare & Medicaid Services4 and an indication for use in pregnant people, the Dexcom G7 stands poised to have a significant impact in glucose control and quality of life beginning immediately at launch.
One could argue the timing of the US availability of the Dexcom G7 was almost poetic, with the rollout beginning the Friday preceding the 16th International Conference on Advanced Technologies & Treatment for Diabetes (ATTD 2023). With an interest in exploring the company’s push for accessibility and taking a deep dive into the development of the device, the hosts of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives Diana Isaacs, PharmD, continuous glucose monitoring program coordinator and endocrine clinical pharmacist at the Cleveland Clinic, and Natalie Bellini, DNP, an endocrine nurse practitioner with R&B Medical Group, sat down with Jake Leach, chief operating officer with Dexcom.